|Bid||7.50 x 1000|
|Ask||20.01 x 800|
|Day's Range||11.99 - 12.91|
|52 Week Range||10.40 - 60.67|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||98.17|
|Earnings Date||Mar 21, 2022 - Mar 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.88|
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2022.
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?